Finanzen von Corvus Pharmaceuticals Inc (CRVS)CRVSCorvus Pharmaceuticals Inc

Evaluating the bottom line, Corvus Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -35.43%, provide a clear picture of how effectively CRVS converts its operational activities into shareholder value.

In the context of the broader market, CRVS competes directly with industry leaders such as MLTX and ALMS. With a market capitalization of $860.56M, it holds a significant position in the sector. When comparing efficiency, CRVS's gross margin of N/A stands against MLTX's N/A and ALMS's 100.00%. Such benchmarking helps identify whether Corvus Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Corvus Pharmaceuticals has shown volatility in its earnings, with a net income of -$17,959,000 in Q2 2026 and a forward P/E of 0, indicating uncertainty in future profitability. The company's current ratio is strong at 16.16, suggesting good short-term financial health.